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Introduction
Wilms' tumor 1 (WT1) plays a chameleon-like role as a tumor suppressor and as an oncogene (1) . During early development, the absence or mutation of WT1 causes loss of WT1 function, resulting in Wilms' tumor or leukemia (1) . Its transcriptional repression of oncogenic growth factors, transcription factors and receptors, including insulin-like growth factor II (2), transforming growth factor beta (3), androgen receptor (4), epidermal growth factor receptor (EGFR) (5), insulin-like growth factor 1 receptor (6) and also Avian myelocytomatosis virus oncogene cellular homolog (c-Myc) (7) , cyclin E (8) and ornithine decarboxylase (9) , supports WT1 as a tumor suppressor (10) . In contrast, WT1 overexpression is a marker of poor prognosis in leukemia and other cancers, suggesting an oncogenic function (11, 12) . WT1 is required for the epithelial-mesenchymal transition, a metastatic hallmark (13) and is involved in Kras-driven oncogenesis (14) .
WT1 protein isoforms arise from two alternative splicing events and the use of alternative translation initiation sites. An alternative CUG initiation site for WT1 protein synthesis (CUG) translation initiation codon produces a WT1 isoform with a 68 amino acid (aa) N-terminal extension (15) . The importance of the alternative CUG-translated variant is unknown and mice homozygous for an allele unable to encode this 68 aa extension display no obvious phenotype (16) . Functional differences between the isoforms in carcinogenesis are unclear as is the identity of the isoform that is predominantly produced in cells. Until now, most transfection and post-translational modification studies focusing on WT1 were conducted with the canonical AUG initiation site for WT1 protein synthesis (AUG)-translated WT1 (augWT1) (17) (18) (19) (20) (21) . The role of augWT1 in gene expression is still uncertain because transfection of augWT1 resulted in either an up or downregulation of its target gene expression, including egfr, c-myc and bcl-2 (5, 7, (22) (23) (24) . Whether regulation of augWT1-target genes is positive or negative appears dependent on the cellular context in which experiments are performed (10) . Thus, why WT1 acts as a tumor suppressor under certain conditions but as an oncogene under other conditions is still indeterminate.
We identified CUG-translated WT1 (cugWT1) as the primary form of WT1 in various cancer cells and tissues. Overexpression of cugWT1 caused neoplastic transformation and increased expression of egfr, c-myc and bcl-2. In contrast, exogenous expression of augWT1 inhibited cancer cell colony formation and repressed cugWT1 transcriptional activity by interacting with cugWT1 and recruiting histone deacetylase 1 (HDAC1) to target gene promoters. Depletion of WT1 inhibited protein kinase B (AKT)-mediated cell transformation, anchorage-independent growth and xenograft cancer growth in mice. AKT interacted with cugWT1, not augWT1, and phosphorylated Ser62 in cancer cells and tissues. AKT increased the abundance of cugWT1 by blocking F-box/WD repeat-containing protein 8 (FBXW8)-induced ubiquitination and proteasomal degradation. The current study was undertaken to explain the chameleon function of WT1 by examining alternative translational expression of WT1 isoforms in cancer cells and tissues and elucidating mechanisms of transcriptional and translational regulation by HDAC1 and AKT.
Materials and methods

Reagents, cells and antibodies
The pCMV6-cugWT1 (Type B; (+) 17 aa/(−) lysine threonine serine sequence which may or may not be present in different WT1 splice isoforms) was purchased from OriGene Technologies (Rockville, MD). The cugWT1 and augWT1 genes were re-cloned into the pCB6 and pcDNA4-Xpress/His vectors. Cell lines were from ATCC (Manassas, VA). Antibodies specific for WT1 (6F-H2, 6F-H17, C-19) were from Millipore (Billerica, MA) and Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against phosphorylated AKT (pAKT), total AKT, EGFR, c-Myc, B-cell lymphoma 2 (Bcl-2), HDAC1 and the pAKT substrate motif were from Cell Signaling Technology, Inc. (Beverly, MA). The rabbit phospho-cugWT1 (Ser62) antibody was raised against a synthetic peptide, RRSRGApSGSEPQQ (Ab Frontier, Seoul, South Korea).
Mouse xenograft models and embryos
Athymic nude mice were purchased from Jackson Laboratories (Bar Harbor, ME), and SK-MEL-28 (5 × 10 6 ) or HCT116 (2 × 10 6 ) cells were injected into the right flank of each mouse as indicated and xenograft tumor growth was monitored. To isolate embryos, SKH-1 mice were purchased from Charles Rivers (Wilmington, MA). At 6-8 weeks of age, strain-matched female and male mice were mated. Pregnant mice were euthanized by CO 2 asphyxiation using compressed gas on day E6.5, E8.5 or E10.5. Embryos were obtained from the uterine horn and recovered from the decidua.
Western blotting and tissue arrays
Malignant kidney cancer tissues were from Mayo Clinic (Rochester, MN) for Western blot and tissue array analyses. Melanoma (T382a) and skin cancer tissue (SK801) arrays were from Biomax (Rockville, MD). Tissue arrays were incubated with rabbit anti-pAKT (Ser473, 1:200) and mouse anti-WT1 (6F-H17, 1:200) for 16 h at 4°C, followed by incubation with a donkey anti-rabbit antibody conjugated with Cy5 (1:1000) and a donkey anti-mouse antibody conjugated with Cy2 (1:1000) for detection.
Sh-RNA knockdown
The pLKO.1-based Lentiviral vectors (Open Biosystems, Huntsville, AL) encoding sh-RNA against human WT1, FBXW8 or green fluorescent protein (GFP) were transfected into 293T cells together with psPAX2 and pMD2.G helper vectors. After 8 h, the medium was changed and viral supernatant fractions were collected 48 h later and filtered through 0.45 μm cellulose acetate. Cells were infected with viral supernatant fractions together with 1 μg/ml polybrene. After 48 h, transfected cells were selected under 2-3 µg/ ml puromycin treatment for at least 3 days.
In vitro kinase assay
The glutathione S-transferase (GST)-N-terminal fragment of cugWT1 produced in BL21 (DE3) E.coli and the GST-augWT1 recombinant protein from Novus Biologicals (Littleton, CO) were used for an in vitro kinase assay with recombinant active AKT1 (Cell Signaling Technology). Reactions were performed at 30ºC for 30 min in a mixture containing 50 μM unlabeled adenosine triphosphate (ATP) and 10 μCi [γ-32 P] ATP and stopped by addition of 6× sodium dodecyl sulfate (SDS) buffer. Samples were separated by 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized by autoradiography, Western blotting with an antibody to detect the pAKT substrate motif or Coomassie blue staining.
Luciferase reporter assay
The pGL3-promoter vector (Promega, Madison, WI) containing a threetime repeated consensus element sequence for WT1-binding (WT1-CSE) was constructed and transfected into HeLa cells with pCMV6-cugWT1 wild type or S62A mutant and phRL-SV40 vector as an internal control for the luciferase reporter assay. The sequence is 5′-aacgcgtaaa gcgtgggcggg ttaaaa gcgtgggcggg ttaaaa gcgtgggcggg tactc gag a-3′.
Colony formation assay
Cells were transfected with pCMV6 plasmids expressing cugWT1 or augWT1. After 48 h, cells were selected by G418 for 10-14 days and stained with 0.5% crystal violet in 25% methanol. Plates were washed with H 2 O, dried and analysed for colony formation.
Real-time polymerase chain reaction (PCR) and chromatin immunoprecipitation (ChIP) assays
Total RNA was prepared from normal and cancer cells using the RNeasy Plus Mini Kit (QIAGEN GmbH, Valencia, CA) and converted to cDNA using the cDNA Synthesis Master Mix (GenDEPOT, Houston, TX). Expression of each cDNA sample was amplified using SYBR Green Master (Rox) Kit (Roche Applied Science, Indianapolis, IN) and the AB7500 real-time polymerase chain reaction (PCR) system (Applied Biosystems, Carlsbad, CA). Gapdh was used as an internal control. All reactions were in triplicate. ChIP assays were performed as described (25) . ChIP primers used were for the egfr, c-myc or bcl-2 promoter and annealing temperature was 57°C (see Supplementary Information is available at Carcinogenesis Online).
Anchorage-independent cell transformation assay
Epidermal growth factor (EGF)-induced transformation was investigated in HaCaT or JB6 cells expressing Sh-WT1 knockdown or exogenous WT1 gene expression. Cells (8000) were seeded in 0.3% agar medium with or without EGF (10 ng/ml). Two weeks later, colonies were scored using a microscope and the Image-Pro PLUS (vs. 4) computer software program (Media Cybernetics, Silver Spring, MD). The same experiment was performed for various cancer cell lines without EGF stimulation.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis for identifying cugWT1 and phosphorylation sites
To identify endogenous cugWT1 or augWT1 proteins from 293T cell lysates, WT1 precipitates (antibodies 6F-H17, 6F-H2) were separated by 8% SDS-PAGE and silver stained according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). Proteins in excised gel slices were digested with trypsin (100 ng/sample) and eluted as described (26) . To identify phosphorylated sites of WT1, 293T lysates transfected with vectors encoding cugWT1 or constitutively active (CA)-AKT1 were immunoprecipitated with anti-Flag (Sigma, M2). WT1 proteins were eluted and denatured from agarose beads in buffer (7 M urea, 2 M thiourea, 2% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate). Eluted proteins were digested with Glu-C (100 ng/sample, Promega) for 16 h at 37°C and used for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis (27) . The ABSciex TripleTOF™ 5600 system was used to identify WT1 total and phosphorylated peptides. Raw data were processed and searched with ProteinPilot™ software (version 4.0) using the Paragon™ algorithm.
Docking model
The AKT1 crystal structure was derived from the Protein Data Bank (28) (PDB ID:3MVH) and prepared under standard procedures of the Protein Preparation Wizard (Schrödinger Suite 2012). The structure of a WT1 fragment (residues 34-100) was built based on multiple-threading alignments by local meta-threading-server and iterative threading assembly refinement (TASSER) of the protein structure and function predictions program I-TASSER 2.0 (29). The WT1 reconstructed homology structure was used for a 20 ps simulation by standard procedures. AKT1 and WT1 protein-protein docking was performed using protein docking server with interactive molecular graphics program (30) , and we selected the best configuration to represent the binding mode.
Statistical analysis
Data are presented as mean values ± SD of triplicates. Significant differences were determined using Student's t-test and considered significant at P < 0.05.
Results
cugWT1 is overexpressed in cancer cells
The WT1 gene encodes multiple isoforms by combining alternative splicing, alternative translation initiation and RNA editing replacing leucine with proline ( Figure 1a ). Immunofluorescence staining indicated that WT1 is highly expressed in human kidney cancer tissues (Figure 1b We subjected 293T cell lysates to immunoprecipitation (IP) using two different WT1 antibodies, 6F-H17 and 6F-H2. Samples were resolved by electrophoresis, silver stained and subjected to LC-MS/MS (Figure 1d ). WT1 peptides were detected in two excised gel portions (#6, #7) in lanes 1 (6F-H17) and 2 (6F-H2). One WT1 band was located at 65-70 kD and another at 50-57 kD. Moreover, the cugWT1-specific peptide (LGAAEASAER), comprising aa 43-52 of cugWT1, was detected only from the gel slice located at 65-70 kD (lanes 1, 2). Note that the molecular weight of cugWT1 is 62-68 kD and augWT1 is 53-56 kD. The proteins located at 62-70 kD (#6) were identified as cugWT1 and those at 50-57 kD as augWT1 ( Figure 1d ). HSP70 peptides were identified in bands at 72-80 kD (#5), and the band at 52-55 kD (#8) was the immunoglobulin G heavy chain. HaCaT, MDA-MB-468 and WiT49 cells expressed a 62-68 kD protein identified as cugWT1 and a 53-56 kD WT1 protein that was augWT1. Both proteins were depleted by introduction of WT1 specific sh-RNA (Sh-WT1; Figure 1e ).
Distinct expression patterns for alternative translational isoforms of WT1 were detected in early mouse embryonic development. Whole embryos on day E6.5 expressed augWT1 as a major form of WT1 (Figure 1f ; Supplementary Figure 2a , available at Carcinogenesis Online). On day E8.5, embryos expressed similar levels of both cugWT1 and augWT1, and on day E10.5, embryos expressed cugWT1 as a major form. This suggests that changes in the ratio of isoforms might affect early embryonic development and predict different functions for cugWT1 and augWT1.
cugWT1 is highly expressed in numerous cancer cell lines, including skin, colon, pancreatic, lung and breast cancer cells, compared with non-malignant human cell lines, as indicated ( Figure 1g sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then visualized by silver staining. Ten different bands (1-10) were excised from the gel and subjected to liquid chromatography-tandem mass spectrometry analysis. WT1 peptides were detected in two portions of the gel (#6 and #7) in both lanes 1 and 2. The raw data were processed and searched in the UniProt human database using ProteinPilot software. Band #6 was identified as cugWT1 and band #7 as augWT1. (e) HaCaT, MDA-MB-468 and WiT49 cells were infected with a lentivirus expressing Sh-WT1 (#2, #3), and the cell lysates were subjected to Western blotting with an antibody (6F-H17) to detect WT1. (f) Mouse embryos were isolated on day E6.5, E8.5 and E10.5 and analysed for WT1 expression with an antibody (6F-H2) to detect WT1. (g) Cell lysates were prepared from normal (lane1) and cancer cell lines, including skin, lung and breast. Lysates were subjected to immunoblotting (IB) with an antibody to detect WT1. EGF-stimulated HaCaT cells, whereas augWT1 inhibited transformation compared with Mock group (Figure 2e) . Additionally, depleting WT1 and subsequent rescue experiments (i.e. restoring cugWT1 expression) in HaCaT cells (Figure 2f ) and a transformation assay using JB6 Cl41 mouse skin epidermal cells (Supplementary Figure 4b , available at Carcinogenesis Online) further demonstrated an oncogenic role for cugWT1. The tumorpromoting role of cugWT1 and tumor-suppressive effect of augWT1 were further confirmed by soft agar assay using WiT49 and SK-NEP-1 kidney tumor cell lines (Figure 2g) .
Western blotting and real-time RT-PCR showed that ectopic expression of cugWT1 in HaCaT cells increased protein (Figure 2h ) and mRNA (Figure 2i ) expression of EGFR, c-Myc, Bcl-2 and cyclin D1. Conversely, depletion of WT1 had the opposite effect (Supplementary Figure 4c, d , available at Carcinogenesis Online). The tumorigenic effect of cugWT1 and the tumor-suppressive effect of augWT1 was further confirmed by a colony formation assay using several cancer cell lines and showed differential oncogenic effects of cugWT1 and tumor suppressive effects of augWT1 most dramatically (Figure 2j ). Collectively, these data support the importance of cugWT1 in increasing cell transformation, cancer cell growth and target oncogene expression.
The augWT1 isoform acts as a dominant negative to inhibit cugWT1 transcriptional activity
Real-time PCR and western blot analysis showed that the increased target gene expression induced by cugWT1 was inhibited in a dose-dependent manner by ectopic overexpression of augWT1 (Figure 3a and b) . This suggested that augWT1 repressed the transcriptional activity of cugWT1 and indicated that inhibition might be achieved by binding of augWT1 with cugWT1 as a competitor (Figure 3c) . Notably, most published research studies focusing on the binding of WT1 with the promoters of target genes used augWT1, not cugWT1. ChIP assay results using primers based on known binding sites of augWT1 with the egfr, c-myc and bcl-2 promoters showed that cugWT1 also binds the same sites (Figure 3d ). These results signify that although the WT1 isoforms bind at the same sites, cugWT1 binding activates and augWT1 represses promoter activity. Thus, if both isoforms bind at the same promoter site, why does cugWT1, but not augWT1, upregulate the expression of these target genes. HDAC1 is a member of a complex formed with BASP1 and PIP2, which represses WT1 transcriptional activity (31, 32) . IP experiments with 293T and MDA-MB-468 cells revealed endogenous HDAC1 bound with augWT1, but not cugWT1 (Figure 3e) . Furthermore, the repressed expression of WT1-target proteins, EGFR and Bcl-2, by ectopic augWT1 expression, was rescued by HDAC1 inhibition with MS275 (Figure 3f ). These results show that augWT1 represses gene transcription by recruiting HDAC1, providing additional functional and mechanistic evidence explaining why cugWT1 behaves as an oncogene and augWT1 as a tumor suppressor gene.
The cugWT1 protein, but not augWT1, is a direct target of AKT
To determine a role for the additional 68 aa located in the N-terminal of cugWT1, we searched kinase substrate motifs and found that the 68 aa region contains an AKT substrate motif at Ser62 (Figure 4a ). To determine whether AKT phosphorylates WT1 at Ser62, we used GST-fusion proteins containing the 68 aa or augWT1. After incubating the respective GST-fusion proteins with active AKT1 and [γ-32 P], phosphorylation was observed in the protein containing the 68 aa. However, no phosphorylation was detected in the augWT1 region (Figure 4b ). To verify that AKT phosphorylates WT1 at Ser62, we used a WT1 wild type and a point mutant (S62A) for an in vitro kinase assay and the mutant (S62A) blocked phosphorylation by AKT1 (Figure 4c, upper  panel) . This finding was confirmed using a phospho-AKT substrate motif antibody, which recognizes the RXRXXpS/T motif (Figure 4c, lower panels) . To confirm the phosphorylation in cells, we transfected cugWT1 and CA-AKT1 into 293T cells, immunoprecipitated cugWT1, and analysed cugWT1 phosphopeptides by mass spectrometry (Figure 4d ). Two phosphopeptides of WT1 were detected, suggesting that AKT1 phosphorylated Ser62 as well as Ser49, which was suspected to be indirectly phosphorylated by AKT signaling (Figure 4d ). However, no phosphorylated peptide from augWT1 as a substrate for AKT was detected.
Results of endogenous IP showed that AKT binds to WT1 physiologically ( Figure 4e ) and CA-AKT1 and 2 bind cugWT1, rather than augWT1 (Figure 4f; Supplementary Figure 5a , available at Carcinogenesis Online). In an additional experiment, CA-AKT1 bound to fragment 1-119, but not fragments 1-68 or 69-119 (Figure 4g ). To analyse the binding mode of AKT and WT1, we performed homology modeling using University of California San Francisco Chimera (33) . Protein-protein docking suggested that AKT mainly binds to the N-terminal of WT1 
cugWT1 is involved in AKT-mediated tumorigenesis
To investigate the role and relationship of WT1 and AKT in carcinogenesis, we compared the expression of WT1 and pAKT (Ser473) in cancer and normal tissues. Immunofluorescence staining of human skin carcinoma and normal tissues showed increased levels of both WT1 and pAKT in cancer tissues compared with normal ( Figure 5a ). Densitometric analysis of each matched sample indicated that 81% of the cancer tissues exhibited increased levels of WT1 and pAKT, compared with normal control tissues. The average total fluorescence density of WT1 and pAKT in all cancer tissues was 2.1-and 1.8-fold higher (P < 0.001) than the average density of normal tissues, respectively (Figure 5a ). Representative samples of normal and malignant matched tissues showed that the WT1 and pAKT proteins are highly abundant in cancer tissues compared with normal ( Figure 5b ). Ectopic overexpression of AKT1 in HaCaT cells increased EGF-induced cell transformation, whereas WT1 knockdown attenuated EGF-and AKT1-induced transformation (Figure 5c ). These results suggest that WT1 is controlled by AKT1 and plays an important role in AKT1-mediated tumorigenesis.
We generated an antibody to detect phosphorylated WT1 at Ser62, and its specificity was confirmed by Western blot using a HeLa cell lysate transfected with a mutant cugWT1-S62A ( Figure  5d ). In EGF-stimulated HaCaT cells, LY294002, an inhibitor of the PI3-K/AKT signaling pathway, reduced endogenous phosphorylation of cugWT1 on Ser62 and AKT on Ser473, whereas inhibition of the mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinases pathway by PD98059 had no effect on WT1 phosphorylation (Figure 5e ). Additionally, CA-AKT1 increased the phosphorylation and protein level of WT1, whereas a kinase-dead AKT1 (KD-AKT1) had no effect (Figure 5f ). Depletion of WT1 inhibited WT1-target gene expression induced by CA-AKT1 and 2, and the inhibition was especially obvious in Bcl-2 expression (Figure 5g ). Figure 5c , available at Carcinogenesis Online). These results demonstrate that phosphorylation of cugWT1 on Ser62 by AKT is important for AKT-mediated tumorigenesis facilitated through cugWT1-targeted gene expression.
Overexpression of cugWT1 increased gene expression in CA-AKT1-transfected HaCaT cells (Supplementary
Phosphorylation on Ser62 is important for cugWT1 protein stability.
Phosphorylation of cugWT1 on Ser62 was increased in human prostate and breast cancer cells (Figure 6a ) and tissue samples from patients with kidney cancer (Figure 6b ) and corresponded with pAKT levels. Furthermore, HaCaT cells stably expressing cugWT1-S62A exhibited reduced anchorage-dependent and -independent growth, compared with cugWT1 wild-type-transfected cells (Figure 6c and d) . The results of luciferase assays using a reporter vector containing three repeats of a WT1-binding consensus motif (5′-GCGTGGGCG-3′) and the cugWT1-S62A mutant exhibited moderately decreased luciferase activity compared with Although we showed that cugWT1 phosphorylation on Ser62 is involved in the transcriptional regulation of WT1-target genes, we cannot rule out the possibility that Ser62 phosphorylation might increase cugWT1 function through other mechanisms such as changes in protein stability. Because AKT phosphorylates cugWT1 and positively regulates cugWT1 protein level (see Figure 5f and g), we suspected that AKT might regulate cugWT1 stability through its phosphorylation on Ser62. Thus, we compared WT1 turnover between cugWT1 wild type-and cugWT1-S62A mutantexpressing cells in the presence of cycloheximide (CHX). The S62A inactivating mutation reduced cugWT1 stability (Figure 6e, upper  panel) , whereas the S62D-activating mutation increased stability (Supplementary Figure 6c , available at Carcinogenesis Online), supporting an essential role for Ser62 phosphorylation in maintaining cugWT1 stability. Overexpression of active AKT also increased cugWT1 stability (Figure 6e, lower panel) . WT1 levels are reportedly regulated by ubiquitination and proteasomal degradation (18, 34) . Transfection of HA-ubiquitin increased ubiquitination of cugWT1 (Supplementary Figure 6d , available at Carcinogenesis Online). Essentially, overexpression of CA-AKT1 and 2 in cugWT1 wild-type cells attenuated cugWT1 ubiquitination but had little effect on the cugWT1-S62A mutant (Figure 6f ). Collectively, AKT increased cugWT1 protein stability through phosphorylation on Ser62 and consistently upregulated the level of cugWT1 in cancer cells and tissues.
FBXW8 binds and promotes cugWT1 ubiquitination and protein degradation
We used IP to examine several FBXW to identify a ligase for cugWT1 ubiquitination and found that FBXW8 binds to cugWT1 (Supplementary Figure 6e , available at Carcinogenesis Online). FBXW8 induced degradation of cugWT1, which was reduced by MG132, an inhibitor of proteasomal degradation (Figure 7a ). Depletion of FBXW8 increased endogenous cugWT1 levels ( Figure 7b ). Specifically, cugWT1 ubiquitination was induced by FBXW8, but not by FBXW1B, a negative control. The FBXW8-induced ubiquitination of cugWT1 was decreased by CA-AKT1 ( Figure 7c) ; however, ubiquitination of the WT1-S62A mutant was not affected (Figure 7d ). These results show that phosphorylation of cugWT1 on Ser62 by AKT inhibits protein degradation induced by FBXW8.
Discussion
Previous studies with ectopic overexpression of augWT1 and depletion of WT1 sometimes yielded similar results, including growth arrest, gene repression and decreased tumorigenicity (35) (36) (37) . However, si-RNA or sh-RNA theoretically targeting augWT1, actually targeted and inhibited cugWT1, the main form of WT1 in many cancer cells, resulting in growth suppression. Overexpression of augWT1 or depletion of WT1 producing the same phenotype has caused much confusion. For example, how does one explain the observations that Kras-driven lung oncogenesis and Ras-mediated transformation of NIH3T3 cells were inhibited by WT1 depletion (14) and overexpression of augWT1 (36) , respectively? We contend that at least part of the confusion is because the cugWT1 form has not been recognized appropriately. Mostly, cugWT1 was regarded as a non-specific band or was not shown in gel cut photos (38, 39) . One group reported that expression of WT1 in SK-Br3 breast cancer cells was increased by activated HER2/AKT signaling (39) , whereas another group indicated that the WT1 protein or gene was not present in the same cell line (38) . We believe that the band actually corresponded to cugWT1 and provide solid evidence confirming that WT1 is overexpressed in many cancers and that cugWT1 not only exists, but is the major form of WT1 in cancer tissues. Evidence includes the following: (i) quantitative real-time PCR confirms that WT1 mRNA is detectable in most cancer tissues and cells, (ii) sh-RNA blocks both an upper band (62-68 kD) corresponding to cugWT1 and a lower band (52-55 kD) identified as augWT1, (iii) an antibody against Ser62 only detects phosphorylation in cugWT1, (iv) MS/MS data confirm that the upper band is cugWT1 phosphorylated at Ser62-augWT1 does not contain this site and finally and (v) completely blocking WT1 expression decreases anchoragedependent cancer cell growth, but adding back cugWT1 rescues the increased anchorage-dependent cancer cell growth. Overall, our results provide strong evidence that cugWT1 behaves as an oncogene, and augWT1 functions as a tumor suppressor.
To identify the WT1 isoform expressed in cells, cugWT1 was detected as the main form using two different WT1 antibodies (6F-H17 and 6F-H2) (40) . Sh-WT1, LC-MS/MS and quantitative real-time PCR results clearly show that cugWT1 is overexpressed in many cancer cells including SK-Br3, which highly express WT1 mRNA and cugWT1 (Figure 1; Supplementary Figure 2b , available at Carcinogenesis Online).
The transcriptional inhibition of cugWT1 indicates that augWT1 acts as a repressor of cugWT1 by recruiting the transcriptional repressor, HDAC1, resulting in suppression of cugWT1-target gene expression. BASP1, PIP2 and HDAC1 form a complex that represses the transcription activity of WT1 by binding with WT1 (31, 32) . Further studies are needed to determine how cugWT1 escapes transcriptional repressor protein binding and whether a heterodimer of augWT1 and cugWT1 can still recruit HDAC1 to inhibit cugWT1 transcription activity. Our results suggest that the controversial observations surrounding WT1 could depend on the respective levels of augWT1 and cugWT1 present in specific cell lines studied.
Herein, we demonstrated that AKT regulates the function of WT1. Tuna et al (39) . suggested the involvement of AKT in HER2-induced WT1 expression, but analysed augWT1 rather than cugWT1, and therefore did not find the AKT phosphomotif (RXRXXS/T) at Ser62, which is only present in cugWT1. Our studies using a mutant cugWT1-S62A demonstrated that phosphorylation of WT1 by AKT regulates WT1 stability through direct interaction. Because the WT1 mutant reduced, but did not totally block AKT-induced activation of WT1, we cannot exclude the possibility that regulation of WT1 by AKT also occurs through other downstream factors. Processing and degradation of WT1 by the serine protease HtrA2/Omi were recently reported (17) . Proteolysis of WT1 by HtrA2/Omi causes removal of WT1 from its binding sites at gene promoters, leading to alterations in gene regulation that enhance apoptosis. AKT attenuates serine protease activity and pro-apoptotic function of HtrA2/Omi through phosphorylation of Ser212 (41) . This suggests that regulation of WT1 by AKT occurs through inhibition of HtrA2/Omi. The functional importance of modifications such as phosphorylation, ubiquitination, sumoylation and proteolysis by HtrA2/ Omi was studied only with augWT1 (17) (18) (19) (20) (21) . However, because cugWT1 is the major form of WT1 in various cell lines and plays a different role than augWT1, re-evaluation of the effects of post-translational modifications of WT1 with cugWT1 is needed.
Because the aberrantly high expression of WT1 in many cancer cells plays an important role in growth and resistance to chemotherapy, especially leukemia, induction of WT1 degradation might be an effective chemotherapeutic strategy. Pharmacological inhibition of HSP90 and HDAC resulted in ubiquitination and subsequent proteasome-dependent degradation of WT1 (18, 34) . In our studies, we demonstrated that WT1 is a direct target of FBXW8, and FBXW8-induced ubiquitination of WT1 was inhibited by AKT (Figure 7c ). Because EGFR is both a downstream and upstream target, development of WT1 inhibitors might offer a logical strategy for chemoprevention by inhibiting both upstream and downstream oncogenic pathways. To implement this strategy, more studies focusing on regulation of translation and the role of augWT1 and cugWT1 in various cancer types are required.
Overall, depletion of WT1 and ectopic WT1 expression experiments demonstrated the importance of cugWT1 in oncogenesis. Based on our findings (summarized in Figure 7e ), the most likely mechanism accounting for this biological effect involves activation of cugWT1 through its phosphorylation on Ser62 by AKT. Because of the critical role of WT1 in mediating oncogenesis, the stimulatory effects of AKT on WT1 and cell transformation suggest that this family of transcription factors might represent a novel chemotherapeutic target. Overall, findings provide a basis for further exploration of the roles of alternative translated WT1 isoforms in various cancers.
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